News details

The Quebec Heart and Lung Institute – Université Laval is undertaking the world’s first research on the long-term remission of metabolic diseases, such as diabetes, following bariatric surgery. More than 350,000 bariatric operations are completed annually throughout the world, including 730 at the Institute. The surgery has now become known as the only lasting treatment for severe obesity. Currently, no clinical studies have examined the long-term effects of common surgical approaches to metabolic diseases, including type 2 diabetes. This understanding is fundamental considering the steady increase of the disease. In Canada, more than 10 million people live with some form of diabetes or prediabetes. Thanks to an outstanding contribution totalling $3.2 million from Johnson & Johnson Medical Companies, the Canadian Institutes of Health Research (CIHR) and the Fonds de recherche du Québec - Santé, a multidisciplinary team has launched the REMISSION study, a long-term, large-scale clinical trial with 400 obese patients suffering from diabetes. The study won the top award from the Canadian Institutes of Health Research in funding for bariatric care.  
Read the press release from Université Laval [in French only]Learn about the REMISSION study [in French only] Related articles: Personnaliser la chirurgie bariatrique, Le Fil, june 11 2015Chirurgie de l'obésité, Le Journal de Montréal, june 12 2015